课题基金 / 基金详情

EVALUATION OF GRADE OF MALIGNANCY AND ITS CLINICAL USE ON THE BASIS OF SFRP METHYLATION IN ORAL SQUAMOUS CELL CARCINOMA

EVALUATION OF GRADE OF MALIGNANCY AND ITS CLINICAL USE ON THE BASIS OF SFRP METHYLATION IN ORAL SQUAMOUS CELL CARCINOMA
基于SFRP甲基化的口腔鳞状细胞癌恶性程度评价及其临床应用
批准号:
18592223
负责人:
HIRATSUKA Hiroyoshi
金额:
$2.49万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007

项目摘要

项目成果

HIRATSUKA Hiroyoshi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Although mutations of APC, CTNNB1 (β-catenin) and AXIN1 are rare in oral squamous cell carcinoma (OSCC), activation of the Wnt signaling pathway is thought to play an important role in oral carcinogenesis. In the present study, we examined the relationship between Wnt signaling and epigenetic alteration of the secreted frizzled-related protein (SFRP) genes in OSCC. We frequently detected loss of menbrane localization of β-catenin and its cytoplasmic or nuclear accumulation in OSCC cell lines, although these cell lines showed no APC or CTNNB1 (β-catenin) mutations and no methylation of CDH1 (E-cadherin). By contrast, we frequently detected methylation of SFRP1 (7/17, 41%), SFRP2 (16/17, 94%) and SFRP5 (14/17, 82%) in a panel of OSCC cell lines, as well as in specimens of primary tumors collected from 44 OSCC patients (SFRP1, 10/42, 24%; SFRP2, 16/44, 36%; SFRP5, 7/43, 16%). We also observed that OSCC cell lines express various Wnt ligands, and that ectopic expression of SFRPs inhibited cancer cell proliferation. Our results confirm the frequent methylation and silencing of SFRP genes in OSCC, and suggest, that their loss of function contributes to activation of Wnt signaling that leads to cell proliferation during oral carcinogenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
舌癌の郭清範囲に関する検討
舌癌切除范围的思考
DOI: --
发表时间: 2006
期刊: 頭頸部癌 34(4)
影响因子: --
作者: [Ueda, G., Sunakawa, H., Nakamori, K., Shinya, T., Tsuhako, W., Tamura, Y., Kosugi, T., Sato, N., Ogi, K., Hiratsuka, H, Ueda G, 仲盛健治, 仲盛健治]
通讯作者: 仲盛健治
進行・再発口腔扁平上皮癌に対するsurvivin-2Bワクチンの臨床第I相試験
Survivin-2B疫苗治疗晚期/复发性口腔鳞状细胞癌的I期临床试验
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Ueda, G., Sunakawa, H., Nakamori, K., Shinya, T., Tsuhako, W., Tamura, Y., Kosugi, T., Sato, N., Ogi, K., Hiratsuka, H, Ueda G, 仲盛健治, 仲盛健治, Sato N, Yohei Sogabe, 今井 崇, 山本 崇, 小林淳一, 曽我部陽平, 今井 崇, 宮崎晃亘]
通讯作者: 宮崎晃亘
Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells
将 CD40 配体基因转移至人树突状细胞可诱导 NK 介导的针对人癌细胞的抗肿瘤作用
DOI: --
发表时间: 2007
期刊: Int.J.Cancer 120(7)
影响因子: --
作者: [Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S, Molkentin JD, Zou Y, Komuro I, Tomihara K.]
通讯作者: Tomihara K.
Current progress and perspectives for human tumor immunotherapy
人类肿瘤免疫治疗的现状与展望
DOI: --
发表时间: 2006
期刊: Tumor Research 41
影响因子: --
作者: [Sato, N]
通讯作者: N
40
    Development of a novel cancer vaccine that targets oral cancer stem cells
    • 批准号:
      24659901
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2012
    • 负责人:
      HIRATSUKA Hiroyoshi
    • 依托单位:
    Analysis of the β catenin gene abnormality and therapeutic application for oral cancer.
    • 批准号:
      22390388
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.4万
    • 财政年份:
      2010
    • 负责人:
      HIRATSUKA Hiroyoshi
    • 依托单位:
    Combined evaluation of lymph node metastasis in squamous cell carcinoma of the oral cavity
    国内基金
    海外基金
    联合基因组重测序和10× Genomics scRNA-Seq解析乌骨鸡胸肌黑色素转运的分子机制
    • 批准号:
      32072711
    • 项目类别:
      面上项目
    • 资助金额:
      58.0万元
    • 批准年份:
      2020
    • 负责人:
      郭松长
    • 依托单位:
    Journal of Genetics and Genomics
    病理性瘢痕的相关基因及siRNA干扰机制的研究
    • 批准号:
      30471790
    • 项目类别:
      面上项目
    • 资助金额:
      21.0万元
    • 批准年份:
      2004
    • 负责人:
      王春梅
    • 依托单位:
    蛋鸡与肉鸡骨骼肌生长发育差异的分子遗传学基础
    • 批准号:
      30330430
    • 项目类别:
      重点项目
    • 资助金额:
      130.0万元
    • 批准年份:
      2003
    • 负责人:
      朱大海
    • 依托单位: